Acrivon Therapeutics Common Net Income
| ACRV Stock | 1.50 0.06 3.85% |
As of the 11th of February 2026, Acrivon Therapeutics shows the Mean Deviation of 4.77, standard deviation of 7.4, and Risk Adjusted Performance of (0.01). Acrivon Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Acrivon Therapeutics information ratio and kurtosis to decide if Acrivon Therapeutics is priced correctly, providing market reflects its regular price of 1.5 per share. Please also double-check Acrivon Therapeutics Common jensen alpha, which is currently at (0.28) to validate the company can sustain itself at a future point.
Acrivon Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Acrivon Therapeutics' valuation are provided below:There are over one hundred nineteen available fundamental signals for Acrivon Therapeutics Common, which can be analyzed over time and compared to other ratios. All traders should should validate Acrivon Therapeutics' prevailing fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable. Market Cap is likely to drop to about 224.7 M in 2026. Enterprise Value is likely to drop to about 183.4 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -72.5 M | -68.9 M | |
| Net Loss | -28.1 M | -29.5 M | |
| Net Loss | -72.5 M | -68.9 M | |
| Net Loss | (2.42) | (2.54) |
Acrivon | Net Income | Build AI portfolio with Acrivon Stock |
The evolution of Net Income for Acrivon Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Acrivon Therapeutics compares to historical norms and industry peers.
Latest Acrivon Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Acrivon Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Acrivon Therapeutics financial statement analysis. It represents the amount of money remaining after all of Acrivon Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Acrivon Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acrivon Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (80.56 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Acrivon Net Income Regression Statistics
| Arithmetic Mean | (22,741,516) | |
| Coefficient Of Variation | (124.36) | |
| Mean Deviation | 23,328,141 | |
| Median | (5,306,000) | |
| Standard Deviation | 28,282,452 | |
| Sample Variance | 799.9T | |
| Range | 75.2M | |
| R-Value | (0.80) | |
| Mean Square Error | 302.4T | |
| R-Squared | 0.65 | |
| Significance | 0.0001 | |
| Slope | (4,500,296) | |
| Total Sum of Squares | 12798.4T |
Acrivon Net Income History
Other Fundumenentals of Acrivon Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Acrivon Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Acrivon Therapeutics is extremely important. It helps to project a fair market value of Acrivon Stock properly, considering its historical fundamentals such as Net Income. Since Acrivon Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acrivon Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acrivon Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
What growth prospects exist in Biotechnology sector? Can Acrivon capture new markets? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. Valuation analysis balances hard financial data with qualitative growth assessments. While each Acrivon Therapeutics valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Understanding Acrivon Therapeutics requires distinguishing between market price and book value, where the latter reflects Acrivon's accounting equity. The concept of intrinsic value - what Acrivon Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Market sentiment, economic cycles, and investor behavior can push Acrivon Therapeutics' price substantially above or below its fundamental value.
Understanding that Acrivon Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Acrivon Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Acrivon Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Acrivon Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Acrivon Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Acrivon Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Acrivon Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Acrivon Therapeutics Common or generate 0.0% return on investment in Acrivon Therapeutics over 90 days. Acrivon Therapeutics is related to or competes with Pmv Pharmaceuticals, Relmada Therapeutics, Vaxart, Immunic, Tscan Therapeutics, ATyr Pharma, and Cibus Global. Acrivon Therapeutics is entity of United States More
Acrivon Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Acrivon Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Acrivon Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 66.02 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 7.98 |
Acrivon Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acrivon Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Acrivon Therapeutics' standard deviation. In reality, there are many statistical measures that can use Acrivon Therapeutics historical prices to predict the future Acrivon Therapeutics' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (1.03) | |||
| Treynor Ratio | (0.13) |
Acrivon Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 4.77 | |||
| Coefficient Of Variation | (4,938) | |||
| Standard Deviation | 7.4 | |||
| Variance | 54.82 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (1.03) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 66.02 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 7.98 | |||
| Skewness | (0.33) | |||
| Kurtosis | 10.72 |
Acrivon Therapeutics Backtested Returns
Acrivon Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0296, which signifies that the company had a -0.0296 % return per unit of risk over the last 3 months. Acrivon Therapeutics Common exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Acrivon Therapeutics' Mean Deviation of 4.77, standard deviation of 7.4, and Risk Adjusted Performance of (0.01) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.24, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acrivon Therapeutics will likely underperform. At this point, Acrivon Therapeutics has a negative expected return of -0.22%. Please make sure to confirm Acrivon Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Acrivon Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Acrivon Therapeutics Common has insignificant reverse predictability. Overlapping area represents the amount of predictability between Acrivon Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Acrivon Therapeutics price movement. The serial correlation of -0.17 indicates that over 17.0% of current Acrivon Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | -0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Acrivon Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Acrivon Therapeutics Common reported net income of (80.56 Million). This is 123.6% lower than that of the Biotechnology sector and 215.0% lower than that of the Health Care industry. The net income for all United States stocks is 114.11% higher than that of the company.
Acrivon Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acrivon Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acrivon Therapeutics could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics by comparing valuation metrics of similar companies.Acrivon Therapeutics is currently under evaluation in net income category among its peers.
Acrivon Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Acrivon Therapeutics from analyzing Acrivon Therapeutics' financial statements. These drivers represent accounts that assess Acrivon Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Acrivon Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Enterprise Value | 120.8M | 228.0M | 77.3M | 194.4M | 223.5M | 183.4M |
Acrivon Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Acrivon Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Acrivon Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acrivon Therapeutics' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 181.2 K | Geode Capital Management, Llc | 2025-06-30 | 164.4 K | Squarepoint Ops Llc | 2025-06-30 | 152.6 K | Hrt Financial Llc | 2025-06-30 | 145.9 K | Goldman Sachs Group Inc | 2025-06-30 | 140.1 K | Xtx Topco Ltd | 2025-06-30 | 106.1 K | State Street Corp | 2025-06-30 | 67.1 K | Charles Schwab Investment Management Inc | 2025-06-30 | 63.6 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 63 K | Ra Capital Management, Llc | 2025-06-30 | 8.3 M | Sands Capital Ventures, Llc | 2025-06-30 | 2.1 M |
Acrivon Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (75.3 M) | ||||
| Shares Outstanding | 31.56 M | ||||
| Shares Owned By Insiders | 20.56 % | ||||
| Shares Owned By Institutions | 55.18 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Book | 0.40 X | ||||
| EBITDA | (79.55 M) | ||||
| Net Income | (80.56 M) | ||||
| Total Debt | 3.65 M | ||||
| Book Value Per Share | 4.08 X | ||||
| Cash Flow From Operations | (65.67 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (2.12) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 75 | ||||
| Beta | 1.76 | ||||
| Market Capitalization | 49.23 M | ||||
| Total Asset | 196.59 M | ||||
| Retained Earnings | (196.98 M) | ||||
| Working Capital | 164.41 M | ||||
| Net Asset | 196.59 M |
About Acrivon Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acrivon Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.